A collaborative platform to advance drugs with the potential to improve the health and lives of people living with neurological and psychiatric disorders.

Russell L. Chin, MD, is Medical Director at Neurvati Neurosciences and GRIN Therapeutics. Prior to joining Neurvati, Dr. Chin was Medical Director in the Neuromuscular Development Unit at Biogen, where his research focus was on spinal muscular atrophy. He served as project lead and clinical development lead on a collaboration to study the safety and efficacy of an implanted port-catheter system for intrathecal delivery of SPINRAZA (nusinersen). He has also served as medical director for several clinical trials of SPINRAZA.

Dr. Chin completed neurology residency training at New York Presbyterian Hospital and was chief resident at Weill Cornell Medical College, where he completed fellowships in clinical neurophysiology and peripheral neuropathy and was associate professor in the neurology faculty. He worked at the Peripheral Neuropathy Center and has authored publications on various neuropathies including chronic inflammatory demyelinating polyneuropathy (CIDP), neuropathies associated with celiac disease, and small fiber neuropathy (SFN). He also served as director of the EMG Laboratory.

Ashley Horn is an executive assistant at Neurvati Neurosciences and GRIN Therapeutics, supporting the Chief Medical Officer, development and business & finance operations. Prior to Neurvati, Ashley was an executive assistant and office manager at Bessemer Venture Partners. She has also served as executive assistant to C-suite executives at Lindsay Goldberg and Bowery Farming. Her career in administrative and operational work began at Okta, where she ultimately served as global programs and services manager. Ashley holds a BA in psychology from San Francisco State University.

Jemima Monchery is a clinical trial manager at Neurvati Neurosciences and GRIN Therapeutics. She has experience in clinical operations management for both domestic and global studies including working at the site level and with full-service CROs and trial sponsors in areas including oncology, neurology, and rare disease. She began her career at Yale Cancer Center, coordinating early and late phase lung oncology clinical studies. She progressed into biotechnology with a role at Roche, working as a member of the Pharma Research Early Development team working on global clinical trials. She then progressed to leadership roles in the CRO sector, executing end-to-end clinical project management including strategies to improve operational efficiencies. Most recently, Jemima worked at Alexion Pharmaceuticals where she was responsible for execution of operational plans and strategies for a Phase 4 interventional pediatric rare disease study and a neuro observational global registry. She received her BS in biology from Providence College and her MHS in biomedical science from Quinnipiac University.

Vijay Rai is Associate Director of Clinical Operations at Neurvati Neurosciences and GRIN Therapeutics, playing a lead role in planning and executing clinical trials. He has more than a decade of experience in clinical trial management. Before joining Neurvati, Vijay held positions of increasing responsibility in every phase of clinical trial planning and execution at Novartis, Ovid Therapeutics, Allergan, and Pacira Pharmaceuticals. He received his BS in pharmacology and toxicology from Massachusetts College of Pharmacy and Health Sciences. 

Hillary Savoie, PhD, is Director of Community Engagement and Communication at Neurvati Neurosciences and GRIN Therapeutics. She is an internationally recognized leader in patient advocacy in the rare disease community, with extensive experience as a rare disease advocate, patient engagement consultant, and writer on patient advocacy issues. She has a deep personal understanding of the role of patient advocacy as the mother of daughter Esmé, who is medically and developmentally complex. She is the founder of The Cute Syndrome Foundation, an advocacy organization focused on support for individuals and families affected by a rare genetic and developmental encephalopathy. She served as Executive Director at TCSF for nine years and now serves as the organization’s Chair of the board of directors. Her essays and reported features focused on life with medically complex children have been published in news outlets including Romper.com, New York Times, Rolling Stone, and the podcast Story Collider, among others. She holds a doctorate in communication and rhetoric from Rensselaer Polytechnic Institute (RPI).